9/24/2026
NeuroThera and Clearmind expand U.S. patent portfolio
Collaboration focuses on LSD, ketamine, and ibogaine combinations.
Topic archive
lsd
5 stories
9/23/2026
NeuroThera expands U.S. patents for psychedelic therapies
New patents cover LSD, ketamine, ibogaine combinations for mental health.
9/23/2026
Clearmind expands U.S. patent portfolio with new applications
Patent applications cover novel combinations of LSD, ketamine, and ibogaine.
9/23/2026
NeuroThera expands U.S. patent portfolio with Clearmind
New patent applications cover LSD, ketamine, and ibogaine combinations for mental health.
8/20/2026
Trump's FDA pick linked to Joe Rogan-backed psychedelic policy
Dr. Heidi Overton, nominated by Trump, expedited psychedelic research policy.